Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 27, Issue , 2016, Pages v69-v82

  Hoelzer, D ^a   Bassan, R ^b   Dombret, H ^c   Fielding, A ^d   Ribera, J M ^e   Buske, C ^f  

^a Onkologikum Frankfurt Am Museumsufer   (Germany)

^b OSPEDALE DELL'ANGELO   (Italy)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM LEUKEMIA; CLINICAL PROTOCOL; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; FOLLOW UP; GENOMICS; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL TIME;

EID: 84995801979     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw025     Document Type: Article

References (100)

1. Sant M, Allemani C, Tereanu C et al. Incidence of hematologic malignancies In Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724-3734.
2. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381:1943-1955.
3. Sant M, Minicozzi P, Mounier M et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 2014; 15: 931-942.
4. Jaffe ES, Harris NL, Stein H et al. Introduction and overview of the classification of the lymphoid neoplasms. In Swerdlow SH, Campo E, Harris NL et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: IARC, 2008; 158-166.
5. Foà R, Guarini A, Vitale A. Approach to the patient with a suspect of ALL. In Goekbuget N, Bassan R, Dombret H et al. (eds), Recommendations of the European Working Group for Adult ALL. Bremen-London-Boston: UNI-MED Verlag AG, 2011; 24-31.
6. Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 2014; 6: e2014073.
7. Bennett JM, Catovsky D, Daniel MT et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981; 47: 553-561.
8. Béné MC, Castoldi G, Knapp W et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9:1783-1786.
9. Béné MC, Nebe T, Bettelheim P et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011; 25: 567-574.
10. Matutes E, Pickl WF, van't Veer M et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 2011; 117: 3163-3171.
11. van Dongen JM, Lhermitte L, Böttcher S et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975.
12. Gleissner B, Gökbuget N, Bartram CR et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536-1543.
13. Moorman AV, Harrison CJ, Buck GA et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/ Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189-3197.
14. Pullarkat V, Slovak ML, Kopecky KJ et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 2008; 111: 2563-2572.
15. Mancini M, Scappaticci D, Cimino G et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA0496 protocol. Blood 2005; 105: 3434-3441.
16. Roberts KG, Li Y, Payne-Turner D et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371:1005-1015.
17. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R et al. Toward a NOTCH1/ FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013; 31: 4333-4342.
18. Coustan-Smith E, Mullighan CG, Onciu M et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10:147-156.
19. Brüggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012; 120: 4470-4481.
20. Hoelzer D, Thiel E, Löffler H et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71:123-131.
21. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 2010; 150:389-405.
22. Brüggemann M, Schrauder A, Raff T et al. Standardized MRD quantification in European ALL trials. In: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521-535.
23. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010: 7-12.
24. Garand R, Beldjord K, Cavé H et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia 2013; 27: 370-376.
25. Holowiecki J, Krawczyk-Kulis M, Giebel S et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia: the Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol 2008; 142: 227-237.
26. Patel B, Rai L, Buck G et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010; 148: 80-89.
27. Beldjord K, Chevret S, Asnafi V et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 2014; 123: 3739-3749.
28. Brüggemann M, Raff T, Flohr T et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107:1116-1123.
29. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120:1868-1876.
30. Bassan R, Spinelli O, Oldani E et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153-4162.
31. Ribera JM, Oriol A, Morgades M et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol 2014; 32:1595-1604.
32. Bassan R, Spinelli O, Oldani E et al. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J 2014; 4: e225.
33. Dhédin N, Huynh A, Maury S et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood 2015; 125: 2486-2496.
34. Hoelzer D, Gökbuget N. Change in prognostic factors. Leukemia 2012; 1(Suppl. 1): S1-S2.
35. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532-543.
36. Annino L, Vegna ML, Camera A et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863-871.
37. Gökbuget N, Bassan R, Dombret H et al. Recommendations of the European Working Group for Adult ALL (EWALL), 1st edition. Bremen: UNI-MED Science Verlag, 2011.
38. Labar B, Suciu S, Willemze R et al. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica 2010; 95: 1489-1495.
39. Marks DI, Paietta EM, Moorman AV et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114: 5136-5145.
40. Hoelzer D, Walewski J, Döhner H et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 2014; 124: 3870-3879.
41. Lazarus HM, Richards SM, Chopra R et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006; 108: 465-472.
42. Ram R, Wolach O, Vidal L et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol 2012; 87: 472-478.
43. Ribera JM, Ribera J, Genescà E. Treatment of adolescent and young adults with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 2014; 6: e2014052.
44. Burke PW, Douer D. Acute lymphoblastic leukemia in adolescents and young adults. Acta Haematol 2014; 132: 264-273.
45. McNeer JL, Raetz EA. Acute lymphoblastic leukemia in young adults: which treatment? Curr Opin Oncol 2012; 24: 487-494.
46. Rytting ME, Thomas DA, O'Brien SM et al. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 2014; 120: 3660-3668.
47. Gökbuget N, Beck J, Brandt K et al. Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35 years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol; results of 1529 AYAs in 2 consecutive trials of the German Multicenter Study Group For Adult ALL (GMALL). Blood (ASH Annual Meeting Abstracts) 2013; 122: abstr 839.
48. Huguet F, Leguay T, Raffoux E et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27: 911-918.
49. DeAngelo DJ, Stevenson KE, Dahlberg SE et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 2015; 29: 526-534.
50. Guru Murthy GS, Venkitachalam R, Mehta P. Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database. Leuk Lymphoma 2015; 56: 2296-2300.
51. Gökbuget N. How I treat older patients with ALL. Blood 2013; 122: 1366-1375.
52. Ribrag V, Koscielny S, Bouabdallah K et al. Addition of rituximab improves outcome of HIV negative patients with Burkitt Lymphoma treated with the Lmba protocol: results of the randomized intergroup (GRAALL-Lysa) LMBA02 protocol. (IGR sponsored LMBA02, NCT00180882). Blood (ASH Annual Meeting Abstracts) 2012; 120: abstr 685.
53. Thomas DA, O'Brien S, Faderl S et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28: 3880-3889.
54. Kantarjian H, Thomas D, Jorgensen J et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012; 13: 403-411.
55. Topp MS, Kufer P, Gökbuget N et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-2498.
56. Topp MS, Gökbuget N, Stein AS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16: 57-66.
57. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra38.
58. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.
59. Gökbuget N, Basara N, Baurmann H et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011; 118: 3504-3511.
60. DeAngelo DJ, Yu D, Johnson JL et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007; 109: 5136-5142.
61. Dombret H, Gabert J, Boiron JM et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357-2366.
62. Fielding AK, Rowe JM, Richards SM et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009; 113: 4489-4496.
63. Thomas DA, Faderl S, Cortes J et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396-4407.
64. de Labarthe A, Rousselot P, Huguet-Rigal F et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408-1413.
65. Ribera JM, Oriol A, González M et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95: 87-95.
66. Fielding AK, Rowe JM, Buck G et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014; 123: 843-850.
67. Bassan R, Rossi G, Pogliani EM et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28: 3644-3652.
68. Pfeifer H, Goekbuget N, Völp C et al. Long-term outcome of 335 adult patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood (ASH Annual Meeting Abstracts) 2010; 116: abstr 173.
69. Chalandon Y, Thomas X, Hayette S et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 2015; 125: 3711-3719.
70. Pfeifer H, Wassmann B, Bethge W et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1 -positive acute lymphoblastic leukemia. Leukemia 2013; 27: 1254-1262.
71. Ravandi F, Jorgensen JL, Thomas DA et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 2013; 122: 1214-1221.
72. (r)) and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 Study. Blood (ASH Annual Meeting Abstracts) 2012; 120: abstr 666.
73. Martinelli G, Iacobucci I, Storlazzi CT et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009; 27: 5202-5207.
74. van der Veer A, Zaliova M, Mottadelli F et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014; 123: 1691-1698.
75. Wassmann B, Pfeifer H, Goekbuget N et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108: 1469-1477.
76. Ribera JM, García O, Montesinos P et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol 2012; 159: 78-81.
77. Foà R, Vitale A, Vignetti M et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118: 6521-6528.
78. Giebel S, Labopin M, Gorin NC et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer 2014; 50: 411-417.
79. Wetzler M, Watson D, Stock W et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 2014; 99: 111-115.
80. Ljungman P, Bregni M, Brune M et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
81. Dombret H, Cluzeau T, Huguet F, Boissel N. Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep 2014; 9: 158-164.
82. Nishiwaki S, Miyamura K, Ohashi K et al. Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Ann Oncol 2013; 24: 1594-1602.
83. Oliansky DM, Camitta B, Gaynon P et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant 2012; 18: 979-981.
84. Marks DI, Woo KA, Zhong X et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 2014; 99: 322-328.
85. Atsuta Y, Suzuki R, Nagamura-Inoue T et al. Disease-specificanalyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113: 1631-1638.
86. Goldstone AH, Richards SM, Lazarus HM et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.
87. Yanada M, Naoe T, Iida H et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 867-872.
88. Mohty M, Labopin M, Volin L et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116: 4439-4443.
89. Marks DI, Moorman AV, Chilton L et al. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/ MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica 2013; 98: 945-952.
90. Soverini S, Gnani A, Colarossi S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009; 114: 2168-2171.
91. Fielding AK, Richards SM, Chopra R et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109: 944-950.
92. Weston BW, Hayden MA, Roberts KG et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 2013; 31: e413-e416.
93. Oriol A, Vives S, Hernández-Rivas JM et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010; 95: 589-596.
94. Gökbuget N, Stanze D, Beck J et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 120: 2032-2041.
95. Tavernier E, Boiron JM, Huguet F et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21: 1907-1914.
96. Kantarjian H, Thomas D, Jorgensen J et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013; 119: 2728-2736.
97. Specchia G, Pastore D, Carluccio P et al. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol 2005; 84: 792-795.
98. Hijiya N, Thomson B, Isakoff MS et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011; 118: 6043-6049.
99. O'Brien S, Schiller G, Lister J et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013; 31: 676-683.
100. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.